16:03 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting CDC25A, CDC25B and CDC25C could help treat breast cancer. In breast cancer patients, high tumor levels of CDC25A, CDC25B and CDC25C correlated with poor...
08:00 , Feb 9, 2012 |  BC Innovations  |  Cover Story

Bringing on the BRAF

The BRAF inhibitor Zelboraf vemurafenib from Daiichi Sankyo Co. Ltd. and Roche produces about an 80% response rate in its approved indication of BRAF-mutant melanoma but only about a 5% rate in colorectal tumors with...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Debiopharm S.A., Ipsen deal

Ipsen granted Debiopharm an exclusive, worldwide license to Debio 0931 (formerly IRC-083864) to treat cancer. The cell division cycle 25C ( CDC25C, CDC25) inhibitor is in preclinical testing. Debiopharm is responsible for all...
08:00 , Jan 16, 2006 |  BioCentury  |  Strategy

Ipsen's pipeline

Ipsen's pipeline Product Description Indication Status Partner Oncology Decapeptyl (A) Decapeptyl in combination with estrogen suppressant agents Premenopausal breast cancer Ph III Decapeptyl (A) Long-acting (4 months) formulation of a decapeptide analog of LHRH...
08:00 , Feb 19, 2002 |  BC Week In Review  |  Company News

National Institute of Health other research news

Researchers published in Nature Genetics that in a breast cancer cell line, BRCA1 regulated DNA-damage induced mitotic arrest at the G2/M checkpoint by inhibiting Cdc2/cyclin B kinase. BRCA1 expression inhibited cyclin B kinase by localizing...
07:00 , Jun 3, 1996 |  BC Week In Review  |  Company News

Mitotix, BASF Pharma deal

The companies entered into a five-year agreement to develop cancer drugs that target cdc25, a family of enzymes involved in regulation of the cell division cycle. The collaboration will combine Mitotix's cell cycle expertise, targets...
07:00 , Sep 18, 1995 |  BC Week In Review  |  Company News

Mitotix other research news

The Cambridge, Mass., company and collaborators published the discovery that CDC25 phosphatase enzymes can serve as oncogenes. As reported in Science, high levels of the enzymes keep cell division going. The enzymes normally serve...
07:00 , Aug 28, 1995 |  BC Week In Review  |  Clinical News

Mitotix regulatory update

Mitotix received U.S. Patent Nos. 5,441,880 and 4,443,962. The '880 patent, to which Mitotix has an exclusive worldwide license, issued to the Cold Spring Harbor Laboratory and covers human and recombinant versions of the proteins...